Fig. 2: MLH1 loss in ER+, nominally HER2− breast cancer cells upregulates membrane-bound HER2. | Nature Communications

Fig. 2: MLH1 loss in ER+, nominally HER2− breast cancer cells upregulates membrane-bound HER2.

From: Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Fig. 2

A Western blots demonstrating increase in pHER2 and downstream signaling in shMLH1 MCF7 cells treated with fulvestrant relative to shLuc cells. Quantification of four independent replicates conducted through ImageJ in accompanying dot plots. Validation in T47D cells in Fig. S3A. Immunofluorescent staining for HER2 in MCF7 shLuc and shMLH1 cells in vitro (B), in MCF7 shLuc and shMLH1 xenograft tumors (C), and in WHIM20, PMS2 mutant, ER+/HER2− PDX tumors (D), grown with or without fulvestrant. Accompanying quantification presented as strip charts. Three independent experiments or tumors from each group were quantified. Two-sided Student’s t test determined p values. Supporting data from FACS analysis are presented in Fig. S3B, C. Scale bars represent 50 µ. Source data for all figures available with paper.

Back to article page